Research Overview
Manufacturing a rapid biologic response
Article first published online: 12 JUN 2009
DOI: 10.1002/ddr.20306
© 2009 Wiley-Liss, Inc.
Issue
1098-2299/asset/cover.gif?v=1&s=c8b6d95b3bde54896854147d5045c8f3690d6eff)
Drug Development Research
Special Issue: Biodefense Countermeasure Development
Volume 70, Issue 4, pages 288–295, June 2009
Additional Information
How to Cite
Latham, P. W. (2009), Manufacturing a rapid biologic response. Drug Development Research, 70: 288–295. doi: 10.1002/ddr.20306
Publication History
- Issue published online: 12 JUN 2009
- Article first published online: 12 JUN 2009
- Abstract
- References
- Cited By
Keywords:
- biologics;
- manufacturing;
- rapid response
Abstract
There are two major components in making new biologic medical countermeasures available for bio-defense and pandemic response: (1) the detection/discovery of effective countermeasures, and (2) their subsequent Process Development (PD) and manufacture. PD and manufacturing, however, are often the most costly and time-consuming parts of the process, potentially taking years and costing hundreds of millions to billions of dollars. To address these long timelines, governments have historically stockpiled countermeasures for known biothreats. Unfortunately, this kind of stockpiling is very expensive, and does not provide protection against novel threats. Fortunately, there currently exist many new technologies that, when combined strategically, have the potential to significantly reduce the time and cost associated with the PD and manufacturing of biologic countermeasures. Drug Dev Res 70:288–295, 2009. © 2009 Wiley-Liss, Inc.

1098-2299/asset/DDR_centre.gif?v=1&s=0de46fc8e2686c185b44eedd0a5a3895cd6d9afe)